how to deposit in 188 jili

how to deposit in 188 jili Where Is JonBenet Ramsey's Brother Burke? Inside His Life After Her MurderPain Clinic In Denver Proudly Offered by Denver Pain Management Clinic

The Titans have issues to fix and hope to keep slim playoff hopes alive when they host the JagsVega-C Rocket Marks Triumphant Return to Space

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares OutstandingUK Eke Celebrates 60th Birthday With Book Launch

washington — President Joe Biden on Monday announced that he is commuting the sentences of 37 of the 40 people on federal death row, converting their punishments to life imprisonment just weeks before President-elect Donald Trump , an outspoken proponent of expanding capital punishment, takes office. The move spares the lives of people convicted in killings , including the slayings of police and military officers, people on federal land and those involved in deadly bank robberies or drug deals, as well as the killings of guards or prisoners in federal facilities. The decision leaves three federal inmates to face execution. They are Dylann Roof, who carried out the 2015 racist slayings of nine Black members of Mother Emanuel AME Church in Charleston, South Carolina; 2013 Boston Marathon bomber Dzhokhar Tsarnaev ; and Robert Bowers, who fatally shot 11 congregants at Pittsburgh’s Tree of life Synagogue in 2018 , the deadliest antisemitic attack in U.S history. “I’ve dedicated my career to reducing violent crime and ensuring a fair and effective justice system,” Biden said in a statement . “Today, I am commuting the sentences of 37 of the 40 individuals on federal death row to life sentences without the possibility of parole. These commutations are consistent with the moratorium my administration has imposed on federal executions, in cases other than terrorism and hate-motivated mass murder.” Reaction was strong, both for and against. A Trump spokesperson called the decision “abhorrent.” “These are among the worst killers in the world and this abhorrent decision by Joe Biden is a slap in the face to the victims, their families, and their loved ones.” said Trump spokesman Steven Cheung. “President Trump stands for the rule of law, which will return when he is back in the White House after he was elected with a massive mandate from the American people.” Heather Turner, whose mother was killed during the 2017 robbery of a Conway, South Carolina, bank, blasted the decision in a social media post, saying Biden didn’t consider the victims of these crimes. “The pain and trauma we have endured over the last 7 years has been indescribable,” Turner wrote on Facebook, describing weeks spent in court in search of justice as “now just a waste of time.” “Our judicial system is broken. Our government is a joke,” she said. “Joe Biden’s decision is a clear gross abuse of power. He, and his supporters, have blood on their hands.” Some of Roof’s victims supported Biden’s decision to leave him on death row. Michael Graham, whose sister Cynthia Hurd was killed by Roof, said Roof’s lack of remorse and simmering white nationalism in the U.S. means Roof is the kind of dangerous and evil person the death penalty is intended for. “This was a crime against a race of people who were doing something all Americans do on a Wednesday night — go to Bible study,” Graham said. “It didn’t matter who was there, only that they were Black.” The Biden administration in 2021 announced a moratorium on federal capital punishment to study the protocols used, which suspended executions during Biden’s term. But Biden actually had promised to go further on the issue in the past, pledging to end federal executions without the caveats for terrorism and hate-motivated, mass killings. While running for president in 2020, Biden’s campaign website said he would “work to pass legislation to eliminate the death penalty at the federal level , and incentivize states to follow the federal government’s example.” Similar language didn’t appear on Biden’s reelection website before he left the presidential race in July. “Make no mistake: I condemn these murderers, grieve for the victims of their despicable acts, and ache for all the families who have suffered unimaginable and irreparable loss,” Biden’s statement said. “But guided by my conscience and my experience as a public defender, chairman of the Senate Judiciary Committee, vice president, and now president, I am more convinced than ever that we must stop the use of the death penalty at the federal level.” He took a political jab at Trump, saying, “In good conscience, I cannot stand back and let a new administration resume executions that I halted.” Trump, who takes office on Jan. 20, has spoken frequently of expanding executions. In a speech announcing his 2024 campaign , Trump called for those “caught selling drugs to receive the death penalty for their heinous acts.” He later promised to execute drug and human smugglers and even praised China’s harsher treatment of drug peddlers. During his first term as president, Trump also advocated for the death penalty for drug dealers . There were 13 federal executions during Trump’s first term, more than under any president in modern history, and some may have happened fast enough to have contributed to the spread of the coronavirus at the federal death row facility in Indiana. Those were the first federal executions since 2003. The final three occurred after Election Day in November 2020 but before Trump left office the following January, the first time federal prisoners were put to death by a lame-duck president since Grover Cleveland in 1889. Biden faced recent pressure from advocacy groups urging him to act to make it more difficult for Trump to increase the use of capital punishment for federal inmates. The president’s announcement also comes less than two weeks after he commuted the sentences of roughly 1,500 people who were released from prison and placed on home confinement during the COVID-19 pandemic, and of 39 others convicted of nonviolent crimes, the largest single-day act of clemency in modern history. The announcement also followed the post-election pardon that Biden granted his son Hunter on federal gun and tax charges after long saying he would not issue one, sparking an uproar in Washington. The pardon also raised questions about whether he would issue sweeping preemptive pardons for administration officials and other allies who the White House worries could be unjustly targeted by Trump’s second administration. Speculation that Biden could commute federal death sentences intensified last week after the White House announced he plans to visit Italy on the final foreign trip of his presidency next month. Biden, a practicing Catholic, will meet with Pope Francis, who recently called for prayers for U.S. death row inmates in hopes their sentences will be commuted. The U.S. Conference of Catholic Bishops, which has long called for an end to the death penalty, said Biden’s decision is a “significant step in advancing the cause of human dignity in our nation” and moves the country “a step closer to building a culture of life.” Martin Luther King III, who publicly urged Biden to change the death sentences, said in a statement shared by the White House that the president “has done what no president before him was willing to do: take meaningful and lasting action not just to acknowledge the death penalty’s racist roots but also to remedy its persistent unfairness.” Madeline Cohen, an attorney for Norris Holder, who faced death for the 1997 fatal shooting of a guard during a bank robbery in St. Louis, said his case “exemplifies the racial bias and arbitrariness that led the President to commute federal death sentences,” Cohen said. Holder, who is Black, was sentenced by an all-white jury. Weissert reported from West Palm Beach, Florida. Associated Press writers Jeffrey Collins in Columbia, South Carolina, and Jim Salter in O’Fallon, Missouri, contributed to this report.

‘Control freak’ Victoria Beckham’s terrifying well-organised day revealed from ice baths to £2k face masks & same meal

SEOUL, South Korea (AP) — Most ruling party lawmakers were boycotting a parliamentary vote Saturday to deny a two-thirds majority sought by the opposition to impeach President Yoon Suk Yeol over his short-lived imposition of martial law , as protests grew nationwide calling for his removal. The likely defeat of the motion is expected to intensify public protests calling for Yoon’s ouster and deepen political chaos in South Korea, with a survey suggesting a majority of South Koreans support the president’s impeachment. Yoon’s martial law declaration drew criticism from his own ruling conservative party, but it is also determined to oppose Yoon's impeachment apparently because it fears losing presidency to liberals. Impeaching Yoon would require support from two-thirds of the National Assembly, or 200 of its 300 members. The opposition parties who brought the impeachment motion have 192 seats, meaning they need at least eight additional votes from Yoon’s People Power Party. The opposition-controlled parliament began a vote earlier Saturday, but only three lawmakers from PPP took part with opposition members. If the number of lawmakers who cast ballots doesn't reach 200, the motion will be scrapped at midnight, according to National Assembly. Opposition parties could submit a new impeachment motion after a new parliamentary session opens next Wednesday. National Assembly Speaker Woo Won Shik urged ruling party members to return to the chamber to participate in the vote, stressing that it was closely watched by the nation and also the world. “Don’t make a shameful judgment and please vote based on your convictions,” Woo said. “I plead to you, for the future of the Republic of Korea.” Earlier Saturday, Yoon issued a public apology over the martial law decree, saying he won’t shirk legal or political responsibility for the declaration and promising not to make another attempt to impose martial law. He said would leave it to his party to chart a course through the country's political turmoil, “including matters related to my term in office." “The declaration of this martial law was made out of my desperation. But in the course of its implementation, it caused anxiety and inconveniences to the public. I feel very sorry over that and truly apologize to the people who must have been shocked a lot,” Yoon said. Since taking office in 2022, Yoon has struggled to push his agenda through an opposition-controlled parliament and grappled with low approval ratings amid scandals involving himself and his wife. In his martial law announcement on Tuesday night, Yoon called parliament a “den of criminals” bogging down state affairs and vowed to eliminate “shameless North Korea followers and anti-state forces.” The turmoil resulting from Yoon’s bizarre and poorly-thought-out stunt has paralyzed South Korean politics and sparked alarm among key diplomatic partners, including neighboring Japan and Seoul’s top ally the United States, as one of the strongest democracies in Asia faces a political crisis that could unseat its leader. Tuesday night saw special forces troops encircling the parliament building and army helicopters hovering over it, but the military withdrew after the National Assembly unanimously voted to overturn the decree, forcing Yoon to lift it before daybreak Wednesday. The declaration of martial law was the first of its kind in more than 40 years in South Korea. Eighteen lawmakers from the ruling party voted to reject Yoon's martial law decree along with opposition lawmakers. The passage of Yoon’s impeachment motion appeared more likely Friday when the chair of Yoon’s party called for his removal on Friday, but the party remained formally opposed to impeachment. On Saturday, tens of thousands of people packed streets near the National Assembly, waving banners, shouting slogans and dancing and singing along to K-pop songs with lyrics changed to call for Yoon’s ouster. A smaller crowd of Yoon’s supporters, which still seemed to be in the thousands, rallied in separate streets in Seoul, decrying the impeachment attempt they saw as unconstitutional. Lawmakers on Saturday first voted on a bill appointing a special prosecutor to investigate stock price manipulation allegations surrounding Yoon’s wife. Some lawmakers from Yoon’s party were seen leaving the hall after that vote, triggering angry shouts from opposition lawmakers. If Yoon is impeached, his powers will be suspended until the Constitutional Court decides whether to remove him from office. If he is removed, an election to replace him must take place within 60 days. Opposition lawmakers say that Yoon’s attempt at martial law amounted to a self-coup, and drafted the impeachment motion around rebellion charges. Lee Jae-myung, the leader of the main liberal opposition Democratic Party, told reporters that Yoon’s speech was “greatly disappointing” and that the only way forward is his immediate resignation or impeachment. On Friday, PPP chair Han Dong-hun, who criticized Yoon's martial law declaration, said he had received intelligence that during the brief period of martial law Yoon ordered the country’s defense counterintelligence commander to arrest and detain unspecified key politicians based on accusations of “anti-state activities." Hong Jang-won, first deputy director of South Korea’s National Intelligence Service, told lawmakers in a closed-door briefing Friday that Yoon called after imposing martial law and ordered him to help the defense counterintelligence unit to detain key politicians. The targeted politicians included Han, Lee and Woo, according to Kim Byung-kee, one of the lawmakers who attended the meeting. The Defense Ministry said it had suspended the defense counterintelligence commander, Yeo In-hyung, who Han alleged had received orders from Yoon to detain the politicians. The ministry also suspended the commanders of the capital defense command and the special warfare command over their involvement in enforcing martial law. Former Defense Minister Kim Yong Hyun, who has been accused of recommending Yoon enforce martial law, has been placed under a travel ban and faces an investigation by prosecutors over rebellion charges. Vice Defense Minister Kim Seon Ho has testified to parliament that it was Kim Yong Hyun who ordered troops to be deployed to the National Assembly after Yoon imposed martial law. Kim Tong-hyung And Hyung-jin Kim, The Associated PressWest Yellowstone police did not release new information as of 3 p.m. Friday regarding the recent death of one of their officers. However, officials did post information online offering help on getting through the grieving process. “The family of Officer Ashlee Stoneburner has requested that in lieu of flowers donations be made to , an organization dedicated to supporting law enforcement officers and their families who are affected by trauma and loss,” the department stated on Facebook. West Yellowstone Police Officer Ashlee Stoneburner “Your generosity can help honor Officer Stoneburner’s legacy and provide vital support to those who serve and protect our community,” the Thursday posting states. Also, on Thursday, West Yellowstone police reminded the public about the 988 suicide and crisis hotline. “It's important to know that there is someone to listen and support in your grief,” officials said. “You are not alone, and reaching out for help is a sign of strength,” the posting states. “Let's spread the word and make sure that everyone knows about this important resource. Take care of yourselves and each other.” The West Yellowstone Police Department announced Stoneburner’s death on Wednesday, adding that an investigation is underway. Circumstances surrounding her death are being investigated by the Madison County Sheriff's Office/Coroner's Office, officials said. Officials said updates will be posted on the West Yellowstone Police Department’s official social media. The department is staffed by 13 people, including a police chief and five officers, with one being a school resource officer, the department's webpage states. The department has seven 911 telecommunicators, one serving as the 911 center manager. Assistant editor Phil Drake can be reached at 406-231-9021. Get local news delivered to your inbox! Assistant editor/reporter {{description}} Email notifications are only sent once a day, and only if there are new matching items.

Here's what the H-1B visa debate with Musk and Ramaswamy is aboutVictor Wembanyama Injury Status – Spurs vs. Pelicans Injury Report December 8

Baseus Blade HD. Adrian Kingsley-Hughes/ZDNET What's the deal? Get 54% off the Baseus Blade HD in this Amazon Black Friday deal plus an extra 17% with an on-page coupon, slashing the price to $43. ZDNET's key takeaways The Baseus Blade HD portable power bank is available on Amazon for $130 It's thin, yet powerful, so it fits perfectly into a laptop bag, and has a clear, easy-to-read display. Because it's big and flat, it takes up a fair bit of desk space. I get so much new stuff to test that I sometimes like revisiting gadgets that I've been using consistently for some time to see how they are holding up. After all, new stuff is cool, but if you're spending your cold, hard-earned cash on something, you want it to last. The other day a reader asked if I was still using the Baseus Blade HD power bank, a product that I'd initially reviewed close to a year ago. Indeed I am. In fact, not only am I using the HD version of this power bank, but I'm also still using the original Blade model, which is now two years old, and both are going strong. Also: I tested the world's fastest SSD and the results will make power users cry So what does HD stand for? High density. Put simply, Baseus used a different battery technology to allow the same charge capacity to be crammed into a smaller space. Baseus Blade HD tech specs Capacity : 20,000mAh silicon-carbon lithium polymer battery : 20,000mAh silicon-carbon lithium polymer battery Ports : 2 x USB-C, 2 x USB-A : 2 x USB-C, 2 x USB-A USB-C Output : 5V/3A | 9V/3A | 12V/3A | 15V/3A | 20V/5A (max 100W) : 5V/3A | 9V/3A | 12V/3A | 15V/3A | 20V/5A (max 100W) USB-C Input : 5V/3.0A | 9V/3.0A | 12V/3.0A | 15V/3.0A | 20V/3.0A (max 60W) : 5V/3.0A | 9V/3.0A | 12V/3.0A | 15V/3.0A | 20V/3.0A (max 60W) USB-A Output : 4.5V/5A | 5V/4.5A |... Adrian Kingsley-HughesAlthough (Reinas) is Switzerland’s entry for the this year, the movie is actually set in Peru and told in Spanish. Director and co-writer Klaudia Reynicke, who left her native Peru at the age of 10, says the film helped her reconnect with her roots after spending most of her life in Europe and the U.S. “I didn’t think it in a conscious way, but I had a need of going back to Peru and shooting something in Spanish,” she said during a panel at Deadline’s Contenders Film: International awards-season showcase. “Now that I have done it,” Reynicke added, “I can see that it was actually very important this reconnection, something has changed. I guess cinema allows this, right?” While is not Reynicke’s own personal story, “it’s definitely very, very connected to it,” she said. The touching family drama — which also has comedic elements — is set in 1992 Peru as the country undergoes social and political upheaval. Single mother Elena is making plans to leave the country with her daughters Lucía and Aurora, but needs their predominantly absent father, Carlos, to sign papers to allow the daughters to cross a border. The girls, whom the well-intentioned but hapless Carlos calls “queens,” are at first skeptical of him. But they eventually warm to their father as the impending farewell from home and family draws ever nearer. This is Reynicke’s third feature, and premiered at Sundance before going on to win the Grand Jury Prize for Best Feature in the Generation Kplus strand of Berlin. In Locarno, it won the Audience Award and took Best Screenplay at the Festival de Lima in Peru. Gonzalo Molina, who plays Carlos, describes the character as “a broken man” who thinks the only way to be forgiven “by these two lovely kids is calling them queens ... Carlos thinks that they are better in many ways than him.” He also “doesn’t know how to repair the damage, but he tries to make things a little better.” Luana Vega, who plays Aurora, says she had to “search for these feelings” when playing “the resentment Aurora has ... Aurora has lived more of this not-present father and Lucía hasn’t, so I think that’s why she tries to take advantage of him.” And yet, the family does come together before parting ways, with Reynicke framing them as a unit. “When you feel that this group of people is becoming a family finally, and the camera embraces them, that’s when you know there is going to be a big separation,” she said. “But to me it’s not really a bad ending, it’s actually life. The family has gained in love and has gained in solidity.” Check back Monday for the panel video. Sign up for . For the latest news, follow us on , , and .

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Neogen Co. ( NASDAQ:NEOG – Free Report ) by 17.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 38,166 shares of the company’s stock after purchasing an additional 5,804 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Neogen were worth $642,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently bought and sold shares of NEOG. Inspire Investing LLC raised its stake in shares of Neogen by 2.7% in the second quarter. Inspire Investing LLC now owns 26,074 shares of the company’s stock worth $408,000 after buying an additional 685 shares during the period. Stephens Inc. AR raised its stake in Neogen by 2.6% during the 3rd quarter. Stephens Inc. AR now owns 35,930 shares of the company’s stock worth $604,000 after acquiring an additional 909 shares during the period. Arizona State Retirement System lifted its holdings in Neogen by 1.9% during the second quarter. Arizona State Retirement System now owns 57,609 shares of the company’s stock valued at $900,000 after purchasing an additional 1,079 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Neogen by 142.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock worth $33,000 after purchasing an additional 1,165 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in shares of Neogen by 3.4% in the second quarter. Commonwealth Equity Services LLC now owns 36,630 shares of the company’s stock worth $573,000 after purchasing an additional 1,190 shares in the last quarter. 96.73% of the stock is currently owned by hedge funds and other institutional investors. Neogen Stock Up 3.6 % Shares of NEOG opened at $12.82 on Friday. The business’s 50 day moving average is $14.59 and its 200 day moving average is $15.58. The company has a current ratio of 4.41, a quick ratio of 2.79 and a debt-to-equity ratio of 0.28. Neogen Co. has a 12-month low of $11.46 and a 12-month high of $20.89. The company has a market capitalization of $2.78 billion, a PE ratio of -116.55 and a beta of 1.21. Insiders Place Their Bets In other news, CEO John Edward Adent bought 14,500 shares of Neogen stock in a transaction dated Friday, October 11th. The shares were purchased at an average cost of $13.80 per share, with a total value of $200,100.00. Following the completion of the acquisition, the chief executive officer now owns 216,477 shares of the company’s stock, valued at $2,987,382.60. This trade represents a 7.18 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website . Corporate insiders own 1.13% of the company’s stock. Wall Street Analyst Weigh In Separately, StockNews.com raised shares of Neogen to a “sell” rating in a report on Monday, September 30th. Read Our Latest Report on Neogen Neogen Profile ( Free Report ) Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. See Also Want to see what other hedge funds are holding NEOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neogen Co. ( NASDAQ:NEOG – Free Report ). Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter .

None

GOJO Shines at ISSA Trade Show, Celebrating Success with Multiple Industry AwardsZurcher Kantonalbank Zurich Cantonalbank increased its stake in Neogen Co. ( NASDAQ:NEOG – Free Report ) by 17.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 38,166 shares of the company’s stock after purchasing an additional 5,804 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Neogen were worth $642,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently bought and sold shares of NEOG. Inspire Investing LLC raised its stake in shares of Neogen by 2.7% in the second quarter. Inspire Investing LLC now owns 26,074 shares of the company’s stock worth $408,000 after buying an additional 685 shares during the period. Stephens Inc. AR raised its stake in Neogen by 2.6% during the 3rd quarter. Stephens Inc. AR now owns 35,930 shares of the company’s stock worth $604,000 after acquiring an additional 909 shares during the period. Arizona State Retirement System lifted its holdings in Neogen by 1.9% during the second quarter. Arizona State Retirement System now owns 57,609 shares of the company’s stock valued at $900,000 after purchasing an additional 1,079 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Neogen by 142.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock worth $33,000 after purchasing an additional 1,165 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in shares of Neogen by 3.4% in the second quarter. Commonwealth Equity Services LLC now owns 36,630 shares of the company’s stock worth $573,000 after purchasing an additional 1,190 shares in the last quarter. 96.73% of the stock is currently owned by hedge funds and other institutional investors. Neogen Stock Up 3.6 % Shares of NEOG opened at $12.82 on Friday. The business’s 50 day moving average is $14.59 and its 200 day moving average is $15.58. The company has a current ratio of 4.41, a quick ratio of 2.79 and a debt-to-equity ratio of 0.28. Neogen Co. has a 12-month low of $11.46 and a 12-month high of $20.89. The company has a market capitalization of $2.78 billion, a PE ratio of -116.55 and a beta of 1.21. Insiders Place Their Bets In other news, CEO John Edward Adent bought 14,500 shares of Neogen stock in a transaction dated Friday, October 11th. The shares were purchased at an average cost of $13.80 per share, with a total value of $200,100.00. Following the completion of the acquisition, the chief executive officer now owns 216,477 shares of the company’s stock, valued at $2,987,382.60. This trade represents a 7.18 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website . Corporate insiders own 1.13% of the company’s stock. Wall Street Analyst Weigh In Separately, StockNews.com raised shares of Neogen to a “sell” rating in a report on Monday, September 30th. Read Our Latest Report on Neogen Neogen Profile ( Free Report ) Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. See Also Want to see what other hedge funds are holding NEOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neogen Co. ( NASDAQ:NEOG – Free Report ). Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter .Intuit’s (NASDAQ:INTU) Q3: Beats On Revenue But Stock Drops

Thor Explorations boss says more to come after jam-packed twelve months - ICYMI

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Prediction: 2 Stocks That Will Be Worth More Than Palantir Technologies 1 Year From Now